Search The Medical Knowledge Base

Search:

Medical News by Category

Acute Coronary Syndrome News

• FDA Advisory Committee rejects Xarelto for Acute Coronary Syndrome
  

  Published: Thursday 24 May 2012

• AstraZeneva and The Medicines Company to co-promote Brilinta in USA
  

  Published: Wednesday 25 April 2012

• Vorapaxar (Merck) plus standard of care significantly reduces risk of Cardiovascular Events
  

  Published: Sunday 25 March 2012

• Cangrelor (AstraZeneca/ The Medicines Company) maintains platelet inhibition and anti-clotting levels prior to Cardiac Surgery
  

  Published: Wednesday 18 January 2012

• Xarelto (Bayer/Janssen) is FDA filed for Acute Coronary Syndrome
  

  Published: Monday 02 January 2012

• Xareto (J&J/Bayer) is FDA filed for Acute Coronary Syndrome
  

  Published: Friday 30 December 2011

• Merck terminates early the TRACER study of vorapaxar in Acute Coronary Syndrome
  

  Published: Tuesday 15 November 2011

• Xarelto(Bayer/Johnson &Johnson) success in ATLAS ACS 2 TIMI 51 study in Acute Coronary Syndrome
  

  Published: Monday 14 November 2011

• Cangrelor (AstraZeneca) maintains platelet inhibition without major bleeding in Acute Coronary Syndrome patients
  

  Published: Saturday 12 November 2011

• NICE final guidance recommends Briique in Acute Coronary Syndrome
  

  Published: Friday 28 October 2011

• AstraZeneca to present positive health economics data on Brilique/Brilinta at ISPOR meeting in November
  

  Published: Friday 21 October 2011

• Brilinta/Brilique is reviewed for ACS by IQWiG the German Health Quality Institute
  

  Published: Saturday 15 October 2011

• Xarelto shows benefit for ACS patients
  

  Published: Saturday 01 October 2011